EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Patient-Reported Outcomes to Inform Tolerability Characterization in Cancer Trials: A Critical Perspective on Unresolved Methodological Issues

Bill Byrom iD, John Devin Peipert iD

Cancer Control · 2026-06 · 33

DOI: 10.1177/10732748261432279 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Control, online erschienen am 03.03.2026. Verfasst von Bill Byrom und 1 weiteren Autor:innen. Beteiligte Einrichtung: eCOA Science, Signant Health, Blue Bell, PA, USA. Hauptthemen laut MEDLINE: Patient Reported Outcome Measures, Neoplasms, Clinical Trials as Topic, Antineoplastic Agents. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patient-reported outcomes assessing treatment toxicity and its impact, and aspects of quality of life, have become increasingly important components of oncology drug development including early phase dose optimization studies. Despite insights from these data, there are limitations on drawing inferences about whether a treatment is tolerable or intolerable, which requires understanding individual risk-benefit assessments that vary between patients, cancer types, and stages of disease. This commentary examines unresolved methodological issues requiring more research rigor and attention: the development of tolerability thresholds based upon toxicity severity data; the direct measurement of tolerability through specific patient self-report measures; and overcoming the challenge of baseline value assessment in important measures such as single item side-effect bother assessments. We call for further research to resolve these challenges and drive more robust inference-making from patient-reported outcomes data collected in cancer clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Patient Reported Outcome MeasuresNeoplasmsClinical Trials as TopicAntineoplastic AgentsHumansQuality of Life

Stichwörter der Autor:innen

cancercancer treatmentpatient-reported outcomestolerabilitytoxicity

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • eCOA Science, Signant Health, Blue Bell, PA, USA.
  • Department of Applied Health Sciences, University of Birmingham, Birmingham, UK.
  • Centre for Patient Reported Outcomes Research, University of Birmingham, Birmingham, UK.

ORCID-Profile: Bill Byrom, John Devin Peipert

Zitieren

APA

Byrom, B., & Peipert, J. D. (2026). Patient-Reported Outcomes to Inform Tolerability Characterization in Cancer Trials: A Critical Perspective on Unresolved Methodological Issues. Cancer Control, 33. https://doi.org/10.1177/10732748261432279

Vancouver

Byrom B, Peipert JD. Patient-Reported Outcomes to Inform Tolerability Characterization in Cancer Trials: A Critical Perspective on Unresolved Methodological Issues. Cancer Control. 2026;33. doi:10.1177/10732748261432279

BibTeX
@article{Byrom2026,
  author = {Byrom, Bill and Peipert, John Devin},
  title = {Patient-Reported Outcomes to Inform Tolerability Characterization in Cancer Trials: A Critical Perspective on Unresolved Methodological Issues},
  journal = {Cancer Control},
  year = {2026},
  volume = {33},
  doi = {10.1177/10732748261432279}
}
Kostenlos starten →